Hanwha Impact invests in U.S.-based Tessera Therapeutics Company's first investment in biotech firm that develops new drugs
Translated by Kim So-in 공개 2022-04-01 10:29:50
이 기사는 2022년 04월 01일 08시06분 thebell에 표출된 기사입니다
Hanwha Impact, formerly known as Hanwha General Chemical, made its first investment in a biotech company that develops new drugs.The company recently invested in U.S.-based early-stage life sciences company Tessera Therapeutics. The investment is said to be small although financial details have not been disclosed.
Hanwha Impact Global, a subsidiary of Hanwha Impact, executed the investment through Hanwha Impact Partners, using capital commitment made by Hanwha Impact. Hanwha Impact has been very active in investments this year, spending a total of 370 billion won ($305 million) so far.
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.
Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
The latest investment marks Hanwha Impact and Hanwha Group’s first investment in a biotech company that develops new drugs. Hanwha Impact hinted at a possibility of investing in biotech firms in May 2021 by adding pharmaceuticals, life science and biotechnology to the business purposes listed in the company’s articles of incorporation. After changing its name from Hanwha General Chemical in September 2021, Hanwha Impact made it clear that it will focus more on investment instead of the petrochemical business.
Hanwha Impact invested in Inari Agriculture, which utilizes next-generation gene editing technologies to create resource-efficient corns and soybeans. It also participated in a Series B funding for Catalog Technologies, a DNA-based data storage solution provider.
Hanwha Group hasn’t invested in the new drug development business since its efforts to develop new drugs failed in the 1990s. Market insiders are paying attention to whether the company will gradually restart the business under the control of Kim Dong-kwan, president and chief executive officer of Hanwha Solutions.
The latest investment was led by Hanwha Impact’s investment strategy division. The company hired new managers to handle bio-related investments earlier this year. (Reporting by Eun-jin Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [i-point]한컴, '2025 재팬 IT 위크 스프링' 참가
- [NPL 경영분석]800억 환입에 순익 4배…대신F&I, '나인원한남 효과'로 도약
- [보험사 CSM 점검]메리츠화재, 보수적 계리정책이 견인한 잔액 증가
- [신협 부실여신 관리 점검]'PF 후폭풍' 신협중앙회, 위기대응 역량 '시험대'
- 우리금융캐피탈, 디지털 영업 경쟁력 강화 사업 착수
- [보험사 기본자본 점검]NH농협생명, 경과조치·보완자본 뺀 손실흡수력은
- [신한금융-더존비즈온 맞손]제주은행 주가 급등한 두 가지 이유
- [금융지주 동일인 지분 점검]JB금융 '3대 주주' OK저축은행 투자 전략 영향은
- [금융사 KPI 점검/KB국민은행]불완전판매 재발 없다, '고객보호·윤리경영' 평가 반영
- [MG캐피탈은 지금]효성에서 새마을금고로, 28년 업력 바탕 새로운 전성기 준비